NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $0.74 -0.08 (-9.70%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About AEON Biopharma Stock (NASDAQ:AEON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AEON Biopharma alerts:Sign Up Key Stats Today's Range$0.73▼$0.8850-Day Range$0.67▼$1.5052-Week Range$0.64▼$17.17Volume164,147 shsAverage Volume564,000 shsMarket Capitalization$29.13 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewAEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Read More… Crypto’s next big bull run? (Ad)Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …And one special coin could do even better. AEON Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScoreAEON MarketRank™: AEON Biopharma scored higher than 33% of companies evaluated by MarketBeat, and ranked 781st out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AEON. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AEON. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders23.50% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AEON Stock News HeadlinesAEON Biopharma maps FDA path for Botox biosimilarOctober 2, 2024 | investing.comBuy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue ProjectionsOctober 2, 2024 | markets.businessinsider.comCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …November 12, 2024 | Weiss Ratings (Ad)AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory MeetingOctober 1, 2024 | markets.businessinsider.comAEON Biopharma, Inc. (AEON) Stock Price, News, Quote & History - Yahoo FinanceAugust 22, 2024 | finance.yahoo.comAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024August 19, 2024 | globenewswire.comAEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | globenewswire.comAEON Biopharma Cuts 55% Of Workforce, Terminates CFO To Preserve Cash; Stock Up In Pre-marketMay 29, 2024 | markets.businessinsider.comSee More Headlines AEON Stock Analysis - Frequently Asked Questions How have AEON shares performed this year? AEON Biopharma's stock was trading at $7.20 on January 1st, 2024. Since then, AEON shares have decreased by 89.6% and is now trading at $0.7510. View the best growth stocks for 2024 here. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are AEON Biopharma's major shareholders? Top institutional shareholders of AEON Biopharma include Caprock Group LLC (0.16%). View institutional ownership trends. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AEON Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Today11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CUSIPN/A CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+532.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-240.45% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.19Miscellaneous Outstanding Shares39,122,000Free Float29,928,000Market Cap$30.91 million OptionableNot Optionable Beta0.40 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:AEON) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.